Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management
Stavra A. Xanthakos, Rohit Kohli – 25 September 2012 – Watch a video presentation of this article
Pediatric nonalcoholic fatty liver disease: Prevalence, diagnosis, risk factors, and management
Stavra A. Xanthakos, Rohit Kohli – 25 September 2012 – Watch a video presentation of this article
Management of nonalcoholic steatohepatitis: Pharmacotherapy
Vlad Ratziu – 25 September 2012 – Watch a video presentation of this article
Management of nonalcoholic fatty liver disease in children
Jean P. Molleston – 25 September 2012 – Watch a video presentation of this article
Histological assessment of nonalcoholic fatty liver disease in adults and children
Elizabeth M. Brunt – 25 September 2012 – Watch a video presentation of this article
Histological assessment of nonalcoholic fatty liver disease in adults and children
Elizabeth M. Brunt – 25 September 2012 – Watch a video presentation of this article
Natural history of nonalcoholic fatty liver disease
Rohini Mehta, Zobair M. Younossi – 25 September 2012 – Watch a video presentation of this article
Assessment and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease
Kathleen E. Corey, Raj Vuppalanchi – 25 September 2012 – Watch a video presentation of this article
Management of nonalcoholic steatohepatitis: Pharmacotherapy
Vlad Ratziu – 25 September 2012 – Watch a video presentation of this article
Projected future increase in aging hepatitis C virus–infected liver transplant candidates: A potential effect of hepatocellular carcinoma
Scott W. Biggins, Kiran M. Bambha, Norah A. Terrault, John Inadomi, Stephen Shiboski, Jennifer L. Dodge, Jane Gralla, Hugo R. Rosen, John P. Roberts – 24 September 2012 – In the United States, the peak hepatitis C virus (HCV) antibody prevalence of 4% occurred in persons born in the calendar years 1940‐1965. The goal of this study was to examine observed and projected age‐specific trends in the demand for liver transplantation (LT) among patients with HCV‐associated liver disease stratified by concurrent hepatocellular carcinoma (HCC).